Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.

Détails

ID Serval
serval:BIB_50C9BDFD646C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
Périodique
Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology
Auteur(s)
Joensuu H., Eriksson M., Collan J., Balk M.H., Leyvraz S., Montemurro M.
ISSN
1879-0887 (Electronic)
ISSN-L
0167-8140
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
116
Numéro
2
Pages
233-238
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
PURPOSE: Gastrointestinal stromal tumor (GIST) has been considered radiation-resistant, and radiotherapy is recommended only for palliation of bone metastases in current treatment guidelines. No registered prospective trial has evaluated GIST responsiveness to radiotherapy.
PATIENTS AND METHODS: Patients with GIST progressing at intra-abdominal sites or the liver were entered to this prospective Phase II multicenter study (identifier NCT00515931). Metastases were treated with external beam radiotherapy using either conformal 3D planning or intensity modulated radiotherapy and conventional fractionation to a cumulative planning target volume dose of approximately 40 Gy. Systemic therapy was maintained unaltered during the study.
RESULTS: Of the 25 patients entered, 19 were on concomitant tyrosine kinase inhibitor therapy, most often imatinib. Two (8%) patients achieved partial remission, 20 (80%) had stable target lesion size for ⩾3 months after radiotherapy with a median duration of stabilization of 16 months, and 3 (12%) progressed. The median time to radiotherapy target lesion progression was 4-fold longer than the median time to GIST progression at any site (16 versus 4 months). Radiotherapy was generally well tolerated.
CONCLUSIONS: Responses to radiotherapy were infrequent, but most patients had durable stabilization of the target lesions. GIST patients with soft tissue metastases benefit frequently from radiotherapy.
Mots-clé
Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Female, Gastrointestinal Neoplasms/drug therapy, Gastrointestinal Neoplasms/radiotherapy, Gastrointestinal Stromal Tumors/drug therapy, Gastrointestinal Stromal Tumors/radiotherapy, Humans, Male, Middle Aged, Prospective Studies, Protein Kinase Inhibitors/therapeutic use, Protein-Tyrosine Kinases/antagonists & inhibitors, Radiotherapy Planning, Computer-Assisted
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/11/2015 18:38
Dernière modification de la notice
08/05/2019 18:32
Données d'usage